Pfizer Raises Outlook Amid Strong Demand for Non-Covid Products

The drugmaker’s revenue was boosted by several acquired products and recent commercial launches, which offset a decline from its Covid-19 vaccine Comirnaty, and unfavorable foreign currency translation.